Table 1.

SNPs in pairwise LD at FGFR2, and in pairwise LD at ENO4, are consistently associated with breast cancer

SNP	Locus	Variant	Study	OR (95% CI)	P
rs1219648	10q26.13	G	NBC	1.25 (1.08–1.44)	0.0025
	123,346,190 bp		CGEMS	1.33 (1.19–1.50)	1.49 × 10⁻⁶
	FGFR2		CBCS	1.23 (1.10–1.38)	3.57 × 10⁻⁴
rs11200014	10q26.13	T	NBC	1.25 (1.08–1.44)	0.0024
	123,334,930 bp		CGEMS	1.31 (1.17–1.48)	4.41 × 10⁻⁶
	FGFR2		CBCS	1.20 (1.07–1.34)	0.0018
rs2420946	10q26.13	T	NBC	1.24 (1.07–1.43)	0.0042
	123,351,324 bp		CGEMS	1.34 (1.19–1.51)	1.18 × 10⁻⁶
	FGFR2		CBCS	1.19 (1.06–1.33)	0.0024
rs2981579	10q26.13	T	NBC	1.25 (1.08–1.44)	0.0024
	123,337,335 bp		CGEMS	1.31 (1.17–1.48)	4.41 × 10⁻⁶
	FGFR2		CBCS	1.20 (1.07–1.34)	0.0018
rs1626678	10q25.3	G	NBC	1.19 (1.03–1.37)	0.016
	118,576,146 bp		CGEMS	1.19 (1.06–1.33)	0.0036
	ENO4		CBCS	1.15 (1.03–1.29)	0.013
rs1681723	10q25.3	A	NBC	1.17 (1.02–1.34)	0.030
	118,591,615 bp		CGEMS	1.17 (1.04–1.31)	0.0090
	ENO4		CBCS	1.12 (1.00–1.25)	0.049
rs740363	10q25.3	C	NBC	1.18 (1.02–1.36)	0.022
	118,575,606 bp		CGEMS	1.17 (1.05–1.32)	0.0065
	ENO4		CBCS	1.14 (1.02–1.28)	0.021

The four SNPs in the second intron of FGFR2 have pairwise LD values ≥ 0.84, whereas those near ENO4 have pairwise LD values ≥ 0.90. FGFR2 and ENO4 are 4.7 MB apart, not in linkage disequilibrium with each other. SNP nucleotide positions are given for human genome build GRCh37/hg19.